JP2014504851A5 - - Google Patents

Download PDF

Info

Publication number
JP2014504851A5
JP2014504851A5 JP2013540008A JP2013540008A JP2014504851A5 JP 2014504851 A5 JP2014504851 A5 JP 2014504851A5 JP 2013540008 A JP2013540008 A JP 2013540008A JP 2013540008 A JP2013540008 A JP 2013540008A JP 2014504851 A5 JP2014504851 A5 JP 2014504851A5
Authority
JP
Japan
Prior art keywords
nucleic acid
seq
polypeptide
bacterium
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013540008A
Other languages
English (en)
Japanese (ja)
Other versions
JP5998370B2 (ja
JP2014504851A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/061164 external-priority patent/WO2012068360A1/en
Publication of JP2014504851A publication Critical patent/JP2014504851A/ja
Publication of JP2014504851A5 publication Critical patent/JP2014504851A5/ja
Application granted granted Critical
Publication of JP5998370B2 publication Critical patent/JP5998370B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013540008A 2010-11-17 2011-11-17 Egfrviiiに対する免疫応答を誘発する方法および組成物 Expired - Fee Related JP5998370B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41485010P 2010-11-17 2010-11-17
US61/414,850 2010-11-17
PCT/US2011/061164 WO2012068360A1 (en) 2010-11-17 2011-11-17 Methods and compositions for inducing an immune response to egfrviii

Publications (3)

Publication Number Publication Date
JP2014504851A JP2014504851A (ja) 2014-02-27
JP2014504851A5 true JP2014504851A5 (enExample) 2015-01-08
JP5998370B2 JP5998370B2 (ja) 2016-09-28

Family

ID=46084412

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013540008A Expired - Fee Related JP5998370B2 (ja) 2010-11-17 2011-11-17 Egfrviiiに対する免疫応答を誘発する方法および組成物

Country Status (17)

Country Link
US (3) US9200057B2 (enExample)
EP (1) EP2640842B1 (enExample)
JP (1) JP5998370B2 (enExample)
CN (1) CN103415620B (enExample)
CA (1) CA2818353A1 (enExample)
CY (1) CY1120622T1 (enExample)
DK (1) DK2640842T3 (enExample)
ES (1) ES2684684T3 (enExample)
HR (1) HRP20181343T1 (enExample)
HU (1) HUE039747T2 (enExample)
LT (1) LT2640842T (enExample)
PL (1) PL2640842T3 (enExample)
PT (1) PT2640842T (enExample)
RS (1) RS57630B1 (enExample)
SI (1) SI2640842T1 (enExample)
SM (1) SMT201800444T1 (enExample)
WO (1) WO2012068360A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
ES3005233T3 (en) 2010-10-01 2025-03-14 Modernatx Inc Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
SI2640842T1 (sl) * 2010-11-17 2018-09-28 Aduro Biotech, Inc. Postopki in sestavki za induciranje imunskega odziva na EGFRvIII
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2763701B1 (en) 2011-10-03 2018-12-19 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
JP2015501844A (ja) 2011-12-16 2015-01-19 モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. 修飾ヌクレオシド、ヌクレオチドおよび核酸組成物
WO2013151663A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of membrane proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
NZ702392A (en) 2012-06-08 2017-03-31 Aduro Biotech Compositions and methods for cancer immunotherapy
HK1213008A1 (zh) 2012-11-06 2016-06-24 艾杜罗生物科技公司 兼性减毒细菌种类及其制备和使用方法
ES2921623T3 (es) 2012-11-26 2022-08-30 Modernatx Inc ARN modificado terminalmente
EA201590396A1 (ru) 2012-12-13 2015-12-30 Адуро Биотек, Инк. Композиция, содержащая циклические пуриновые динуклеотиды с определенной стереохимией, и способ ее получения и применения
MX2015008329A (es) 2012-12-27 2016-03-01 Aduro Biotech Inc Compañeros de fusion de peptido, señal que facilita la expresion listeral de secuencias antigenicas y metodos de preparacion y uso de los mismos.
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP2992000B1 (en) 2013-05-03 2020-07-08 The Regents of The University of California Cyclic di-nucleotide induction of type i interferon
US9549944B2 (en) 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
ME03586B (me) 2013-05-18 2020-07-20 Univ California Sastavi i metode za aktiviranje signaliziranja koje je zavisno od .,stimulatora gena za interferon"
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
AU2015250111A1 (en) * 2014-04-24 2016-12-08 Advaxis, Inc. Recombinant listeria vaccine strains and methods of producing the same
US10925945B2 (en) 2014-10-13 2021-02-23 Providence Health & Services-Oregon Bacterial vaccines deficient in the 2-C-methyl-D-erythritol-4-phosphate pathway and methods of preparation and use thereof
US20160228530A1 (en) * 2014-10-14 2016-08-11 The Trustees Of The University Of Pennsylvania Combination therapy for use in cancer therapy
WO2016073381A1 (en) 2014-11-03 2016-05-12 Cerus Corporation Compositions and methods for improved car-t cell therapies
JO3746B1 (ar) 2015-03-10 2021-01-31 Aduro Biotech Inc تركيبات وطرق لتنشيط الإشارات المعتمدة على "منبه أو تحفيز جين انترفيرون"
MA44378A (fr) * 2015-04-13 2019-01-23 Aduro Biotech Inc Protéines de fusion immunogènes pour le traitement du cancer
KR20180002640A (ko) * 2015-04-13 2018-01-08 아두로 바이오테크, 인코포레이티드 표피 성장 인자 수용체 변형 iii-메소텔린 융합체 및 이를 이용하는 방법
US20160316247A1 (en) * 2015-04-27 2016-10-27 Ericsson Ab Program and device class entitlements in a media platform
MA43362A (fr) * 2015-05-26 2018-10-10 Advaxis Inc Immunothérapie à base de vecteurs d'administration personnalisés, et leurs utilisations
MA42263A (fr) * 2015-06-24 2021-03-31 Advaxis Inc Dispositif de fabrication et procédé pour immunothérapie fondée sur un vecteur d'administration personnalisé
KR102883915B1 (ko) 2015-12-16 2025-11-18 시애틀 프로젝트 코포레이션 신생항원 동정, 제조, 및 용도
NL2017267B1 (en) 2016-07-29 2018-02-01 Aduro Biotech Holdings Europe B V Anti-pd-1 antibodies
CN109890834A (zh) * 2016-08-01 2019-06-14 艾杜罗生物科技公司 蛋白质表达增强子序列及其用途
NL2017270B1 (en) 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
WO2019075112A1 (en) 2017-10-10 2019-04-18 Gritstone Oncology, Inc. IDENTIFICATION OF NEO-ANTIGENS USING HOT POINTS
KR20260008173A (ko) 2017-11-22 2026-01-15 시애틀 프로젝트 코포레이션 신생항원에 대한 접합 에피토프 제시 감소
WO2021014398A1 (en) * 2019-07-23 2021-01-28 University Of Rijeka Faculty Of Medicine Integrated human cytomegalovirus / glioblastoma vaccine

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830702A (en) 1990-10-31 1998-11-03 The Trustees Of The University Of Pennsylvania Live, recombinant listeria monocytogenes and production of cytotoxic T-cell response
US5552284A (en) 1991-03-29 1996-09-03 Genentech, Inc. Detection of interleukin-8 receptors by nudeic acid hybridization
IT1262895B (it) 1992-03-02 1996-07-22 Proteina estratta da ceppi citotossici di helicobacter pylori, gene che la esprime, uso della proteina come vaccino o diagnostico.
US6379943B1 (en) 1999-03-05 2002-04-30 Merck & Co., Inc. High-efficiency Cre/loxp based system for construction of adenovirus vectors
US5709999A (en) * 1994-08-12 1998-01-20 Myriad Genetics Inc. Linked breast and ovarian cancer susceptibility gene
US7794729B2 (en) * 1994-11-08 2010-09-14 The Trustees Of The University Of Pennsylvania Methods and compositions for immunotherapy of cancer
US6051237A (en) 1994-11-08 2000-04-18 The Trustees Of The University Of Pennsylvania Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector
WO1996016988A1 (en) * 1994-11-28 1996-06-06 Thomas Jefferson University Reagents and processes for targeting mutant epidermal growth factor receptors
US5888530A (en) 1995-07-21 1999-03-30 The General Hospital Corporation Method of enhancing delivery of a pharmaceutical formulation
US6099848A (en) 1997-11-18 2000-08-08 The Trustees Of The University Of Pennsylvania Immunogenic compositions comprising DAL/DAT double-mutant, auxotrophic, attenuated strains of Listeria and their methods of use
US8021658B2 (en) * 2001-05-25 2011-09-20 Thomas Jefferson University Alternative splice forms of proteins as basis for multiple therapeutic modalities
WO2003102168A1 (en) 2002-05-29 2003-12-11 The Regents Of The University Of California Attenuated listeria spp. and methods for using the same
AU2003259109A1 (en) 2002-07-12 2004-02-02 The Johns Hopkins University Mesothelin vaccines and model systems
DK1592441T3 (da) 2003-02-06 2012-05-14 Aduro Biotech Listeria, hvis indtrængen i ikke-phagocytiske celler er svækket, vacciner omfattende listeria og fremgangsmåder til anvendelse deraf
WO2004084936A2 (en) 2003-02-06 2004-10-07 Cerus Corporation Modified free-living microbes, vaccine compositions and methods of use thereof
US7842289B2 (en) 2003-12-24 2010-11-30 Aduro Biotech Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
CN104857500A (zh) * 2005-11-02 2015-08-26 杜克大学 同时的化学疗法和免疫疗法
WO2007117371A2 (en) 2006-03-01 2007-10-18 Anza Therapeutics, Inc. Engineered listeria and methods of use thereof
EP2860253B1 (en) * 2006-03-01 2018-08-01 Aduro Biotech, Inc. Engineered listeria and methods of use thereof
WO2009012488A1 (en) * 2007-07-19 2009-01-22 Duke University Assay for human anti-egrf variant iii antibodies
CN102076843A (zh) 2008-05-19 2011-05-25 艾杜罗生物科技公司 包含prfa*突变体李斯特菌的组合物及其使用方法
WO2010011870A2 (en) * 2008-07-24 2010-01-28 Anza Therapeutics, Inc. Compositions and methods for the treatment of hepatitis c
TWI580431B (zh) * 2008-08-19 2017-05-01 腫瘤療法 科學股份有限公司 Hig2與urlc10抗原決定位胜肽以及含此胜肽之疫苗
SI2640842T1 (sl) * 2010-11-17 2018-09-28 Aduro Biotech, Inc. Postopki in sestavki za induciranje imunskega odziva na EGFRvIII

Similar Documents

Publication Publication Date Title
JP2016503655A5 (enExample)
JP2010508861A (ja) 抗原およびタンパク質毒素をコードする異種ヌクレオチド配列からなる担体としての微生物、その生成方法、ならびにその使用
CN102046198A (zh) 鞭毛蛋白多肽疫苗
CN112979829B (zh) 融合蛋白及其在制备靶向新冠病毒sars-cov-2的疫苗中的应用
RU2677799C2 (ru) Модифицированные суперспиральные белки с улучшенными свойствами
KR20160130216A (ko) 헤테로올리고머 미코박테리아 항원의 융합물
JP2011529077A (ja) C型肝炎の治療のための組成物および方法
JP2009540801A5 (enExample)
JP2014507146A5 (enExample)
TWI621627B (zh) 用於豬生殖與呼吸綜合症及豬環狀病毒關聯疾病之疫苗組成物
CN103013954B (zh) 水稻基因badh2的定点敲除系统及其应用
US20150017198A1 (en) Mutated and bacteriophage t4 nanoparticle arrayed f1-v immunogens from yersinia pestis as next generation plague vaccines
WO2007125535A1 (en) Recombinant flagellin gene and uses thereof
US9925259B2 (en) Immunogenic polypeptide surface layer-expressing bifidobacterium
CN107723269B (zh) 重组鼠伤寒沙门菌二价疫苗株的构建方法及所得株和应用
WO2022034221A1 (en) Salmonella vaccine for the treatment of coronavirus
CA2730741C (en) Self-replicating vector lacking an antibiotic-resistance gene
Kim et al. Oral administration of Lactococcus lactis expressing Helicobacter pylori Cag7-ct383 protein induces systemic anti-Cag7 immune response in mice
EP3562504B1 (en) Dna vaccine comprising a polynucleotide sequence encoding a fusion protein encompassing a plant protein signal sequence
Aguilera et al. Porcine circovirus type 2 protective epitope densely carried by chimeric papaya ringspot virus–like particles expressed in Escherichia coli as a cost‐effective vaccine manufacture alternative
CN104127883B (zh) 以hsp65为表位支架的多t细胞表位结核基因疫苗
WO2009127766A1 (es) Sistema para la expresión de péptidos sobre la superficie bacteriana
Su-Jung et al. Cloning and expression of hpaA gene of Korean strain Helicobacter pylori K51 in oral vaccine delivery vehicle Lactococcus lactis subsp. lactis MG1363
US20240254167A1 (en) Genetically modified clostridium strains expressing recombinant antigens and uses thereof
CN106170551B (zh) 生产不耐热肠毒素b亚单位的质粒、方法及其套组